Xeris Pharmaceuticals Stock Investor Sentiment
| XERS Stock | USD 4.57 0.18 4.10% |
Slightly above 80 percent of all Xeris Pharmaceuticals' private investors are aggressively thinking of buying. The analysis of overall sentiment of trading Xeris Pharmaceuticals stock suggests that a fairly large number of investors are excited at this time. Xeris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Xeris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Xeris |
Xeris Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Xeris Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Xeris Pharmaceuticals that are available to investors today. That information is available publicly through Xeris media outlets and privately through word of mouth or via Xeris internal channels. However, regardless of the origin, that massive amount of Xeris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Xeris Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Xeris Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Xeris Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Xeris Pharmaceuticals alpha.
Xeris Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 320 shares by Hecht Beth of Xeris Pharmaceuticals at 3.61 subject to Rule 16b-3 | 01/03/2025 |
2 | Xeris Expects to Exceed Full-Year 2024 Financial Guidance | 01/10/2025 |
3 | Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.s PS Ratio - Simply Wall St | 01/30/2025 |
4 | Disposition of 25842 shares by Johnson Kenneth Erland of Xeris Pharmaceuticals at 3.56 subject to Rule 16b-3 | 01/31/2025 |
5 | Acquisition by John Shannon of 800000 shares of Xeris Pharmaceuticals subject to Rule 16b-3 | 02/03/2025 |
6 | Xeris Biopharma Holdings, Inc.s top owners are retail investors with 50 percent stake, while 45 percent is held by institutions | 02/19/2025 |
7 | Disposition of 14037 shares by Hecht Beth of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3 | 02/21/2025 |
8 | Insider Trading | 02/25/2025 |
9 | Xeris Pharmaceuticals Q4 2024 Earnings Preview | 03/05/2025 |
10 | Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results and Announces 2025 Guidance | 03/06/2025 |
11 | Xeris Biopharma Holdings Inc Q4 2024 Earnings Call Highlights Surpassing Revenue ... | 03/07/2025 |
12 | Xeris Biopharma Holdings, Inc. Q4 2024 Earnings Call Transcript | 03/10/2025 |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.